Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RelCoVax versus Corbevax primary COVID-19 vaccination study
PACTR202307772264605Phase 2Not yet recruiting
- Sponsor
- Reliance Life Sciences
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Corbevax in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Reliance Life Sciences. Primary endpoint: Seroconversion rate at day 56 against SARS-CoV-2 neutralizing antibody. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
Corbevax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202307772264605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202307772264605.